Leerink Partners analyst Paul Matteis reiterated an Outperform rating and raised his price target on GW Pharma (NASDAQ: GWPH) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

GW Pharma's (GWPH) Price Target Raised to $152 at Morgan StanleyJune 28, 2016 7:58 AM Zynerba Pharma (ZYNE) Gains in Sympathy with GW Pharma (GWPH)June 27, 2016 9:13 AM GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - LeerinkJune 27, 2016 7:42 AM GW Pharma (GWPH) Announces Positive Top-Line Data from Epidiolex Phase 3June 27, 2016 7:03 AM GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut SyndromeJune 27, 2016 7:00 AM